

Summary of Tyrer-Cuzick Models¹

Tyrer-Cusick v6	Tyrer-Cusick v7	Tyrer-Cusick v8
<ul style="list-style-type: none"> • Age • Menarche age • Parous • Age at first child • Menopause Status • Menopause age • Height & Weight • Hyperplasia (without atypia) • Atypical Hyperplasia • LCIS • Ovarian status • Age at ovarian cancer • Ashkenazi inheritance • HRT use, type, length, intended use length, last use • Genetic test • Father genetic test • For all female relatives (mother, sisters, grandmothers, aunts, daughters, nieces, half-sisters) affected with cancer: <ul style="list-style-type: none"> ➤ Affected status ➤ Bilateral status ➤ Ovarian status ➤ Age ➤ Bilateral age ➤ Ovarian age ➤ Genetic test result 	<p>Major changes from v6</p> <ul style="list-style-type: none"> • The way risk is calculated for women with atypical hyperplasia and LCIS (no other risk factors used in calculation) • Updated and smoothed rates of invasive breast cancer • Updates to the genetic model BRCA assumptions • Updated hormone replacement therapy component • Added competing risks projection to give risk allowing for death from other causes than breast cancer (<i>available in CRA Health's Tyrer-Cuzick v8 release</i>) <p>Minor changes from v6</p> <ul style="list-style-type: none"> • Allowed father or brother to have breast cancer. They are treated the same was as an affected woman aged 35. • Standardized lifetime risk: Charts and predictions to 85 	<p>Major changes from v7</p> <ul style="list-style-type: none"> • Mammographic density added as a risk factor allowing three measures of density: <ol style="list-style-type: none"> 1. Volpara® Volumetric Density 2. Visual Assessment Scale (VAS) Density 3. BI-RADS® ATLAS* Density Breast Composition Measures • Change to atypical hyperplasia model for women with substantial family history • Definition of unknown benign disease updated • Option for polygenic SNP score added <p>Minor changes from v7</p> <ul style="list-style-type: none"> • Addition of Slovenian baseline rates • HRT intended use now defaults to two years

¹ www.ems-trials.org/riskevaluator - IBIS Breast Cancer Risk Evaluation Tool